A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ATR-101 for the Treatment of Cushing's Syndrome
Phase of Trial: Phase II
Latest Information Update: 05 Feb 2018
At a glance
- Drugs Nevanimibe (Primary)
- Indications Cushing syndrome
- Focus Therapeutic Use
- Sponsors Millendo Therapeutics
- 04 Apr 2017 Trial design presented at The 99th Annual Meeting of the Endocrine Society
- 23 Mar 2017 According to a Millendo Therapeutics media release, data from this trial will be presented at The Endocrine Societys (ENDO) 99th Annual Meeting and Expo 2017.
- 20 Feb 2017 Status changed from not yet recruiting to recruiting.